Your browser doesn't support javascript.
loading
Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.
Martins, Frederico S; Zhu, Peijuan; Heinrichs, M Tobias; Sy, Sherwin K B.
Afiliação
  • Martins FS; Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
  • Zhu P; Clinical Pharmacology & Pharmacometrics, Janssen Research & Development LLC, Raritan, NJ, USA.
  • Heinrichs MT; Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Sy SKB; Department of Statistics, State University of Maringá, Paraná, Brazil.
Br J Clin Pharmacol ; 87(3): 1012-1023, 2021 03.
Article em En | MEDLINE | ID: mdl-32638408
AIMS: The objective of the current study was to evaluate paediatric dosing regimens for meropenem plus fosfomycin that generate sufficient coverage against multidrug-resistant bacteria. METHODS: The physiologically based pharmacokinetic (PBPK) models of meropenem and fosfomycin were developed from previously published pharmacokinetic studies in five populations: healthy subjects of Japanese origin, and healthy adults, geriatric, paediatric and renally impaired of primarily Caucasian origins. Pharmacodynamic (PD) analyses were carried out by evaluating dosing regimens that achieved a ≥90% joint probability of target attainment (PTA), which was defined as the minimum of the marginal probabilities to achieve the target PD index of each antibiotic. For meropenem, the percentage of time over a 24-hour period wherein the free drug concentration was above the minimum inhibitory concentration (fT > MIC) of at least 40% was its PD target. The fosfomycin PD index was described by fAUC/MIC of at least 40.8. RESULTS: For coadministration consisting of 20 mg/kg meropenem q8h as a 3-hour infusion and 35 mg/kg fosfomycin q8h also as a 3-hour infusion in a virtual paediatric population between 1 month and 12 years of age with normal renal function and a corresponding body weight between 3 and 50 kg, a joint PTA ≥ 90% is achieved at MICs of 16 and 64 mg/L for meropenem and fosfomycin coadministration, respectively, against Klebsiella pneumoniae and Pseudomonas aeruginosa. CONCLUSION: The current study identified potentially effective paediatric dosing regimens for meropenem plus fosfomycin coadministration against multidrug-resistant bacteria.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pediatria / Fosfomicina Tipo de estudo: Health_economic_evaluation Limite: Adult / Aged / Child / Humans Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pediatria / Fosfomicina Tipo de estudo: Health_economic_evaluation Limite: Adult / Aged / Child / Humans Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido